衛 生 福 利 部
MINISTRY OF HEALTH AND WELFARE

CERTIFICATE OF GOOD MANUFACTURING PRACTICE

Issue Date: April 22, 2022

Issued following an inspection in accordance with Article 57 of the Pharmaceutical Affairs Law and relevant Regulations of the Republic of China (Taiwan).

The competent authority of the Republic of China confirms the following:
The manufacturer: Genovior Biotech Corporation
Site address: No.50-3/4F., No.50-5/4F., No.50-8/3F., No.50-8/4F., No.50-8/5F., No.50-9/5F., Keyan Rd., Zhunan Township, Miaoli County 35053, Taiwan (R.O.C.)
Manufacturer's licence number: (C)0043032

is the manufacturer of medicinal products for human use that has been inspected with the following Active Pharmaceutical Ingredient(s): Azacitidine, Bortezomib, Fulvestrant, Glucagon, Octreotide Acetate, Pemetrexed Disodium Hemipentahydrate, Teriparatide.

From the knowledge gained during GMP inspection performed on February 15-16, 2022, it is considered that the manufacturer complies with the Pharmaceutical Inspection Convention/Co-operation Scheme Guide to Good Manufacturing Practice (PIC/S GMP) Part II (=GMP of WHO/ICH Q7) and Good Distribution Practice (PIC/S GDP) for medicinal products.

This certificate is valid until October 29, 2025.
This certificate may be revoked at anytime as warranted.

Signed by

Shou-Mei Wu

Shou-Mei Wu, Ph.D.
Director-General
Food and Drug Administration
（http://www.fda.gov.tw/TC/index.aspx）

Under the delegated authority of
Shih-Chung Chen, D.D.S.
Minister
Ministry of Health and Welfare
Republic of China (Taiwan)

07835